Nektar chief says they've solved the mystery behind the disastrous 'softening' in patient responses to '214 — spurring a rout among investors - Endpoints News
Nektar chief says they've solved the mystery behind the disastrous 'softening' in patient responses to '214 — spurring a rout among investors - Endpoints News
Summary
Nektar CEO Howard Robin says his top team has been puzzling out the reason why the response rates for their closely-watched drug NKTR-214 (bempegaldesleukin) “softened up” over time — with disastrous consequences. But the explanation didn’t satisfy anyone. In…
My Thoughts
You can't stop the future. You can't rewind the past. The only way to learn the secret...is to press play. This was a great read from Endpts and it really opened my eyes to the possibilities of the future.
Thank you for Reading!
This has been your business news update. Thank you so much for reading. I do my best to bring Steem the most up to date news. Please don't forget to leave your thoughts and comments below.
Warning! This user is on our black list, likely as a known plagiarist, spammer or ID thief. Please be cautious with this post!
If you believe this is an error, please chat with us in the #appeals channel in our discord.